Table 2. Adverse events.
| Adverse events | Comparison groups | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| Anemia17 | 4 (4/90) | - | - | - | - | 5 (1/19) | - | - | - |
| Cataract progression19 | 7 (4/54) | - | - | 6 (3/50) | - | - | 0 (0/52) | - | - |
| Congestive heart failure17 | 1 (1/90) | - | - | - | - | 0 (0/19) | - | - | - |
| Death17 | 2 (2/90)* | - | - | - | - | 0 (0/19) | - | - | - |
| Elevation of blood pressure17 | 1 (1/90) | - | - | - | - | 0 (1/19) | - | - | - |
| Endophthalmitis17 | 1 (1/90) | - | - | - | - | 0 (0/19) | - | - | - |
| Foreign Body sensation22 | - | 13 (2/15) | - | - | - | 0 (0/7) | - | - | - |
| Intraocular pressure rise15,17,20,21,23 | 4 (1/124) | - | 8 (6/70) | - | 0 (0/37) | 0 (0/52) | - | 7 (1/13) | 14 (2/14) |
| Iris neovascularization15 | 22 (9/41) | - | 0 (0/37) | - | 0 (0/37) | - | - | - | - |
| Marked anterior chamber reaction15 | 2 (1/41) | - | 3 (1/37) | - | 0 (0/37) | - | - | - | - |
| Moderate anterior chamber reaction15 | 19 (8/41) | - | 19 (7/37) | - | 0 (0/37) | - | - | - | - |
| Myocardial infarction17 | 2 (2/90) | - | - | - | - | 0 (0/19) | - | - | - |
| Peripheral vascular disease17 | 1 (1/90) | - | - | - | - | 10 (2/19) | - | - | - |
| Pigment epithelial tears19 | 3 (3/54) | - | - | 0 (0/50) | - | - | 0 (0/52) | - | - |
| Posterior vitreous detachment19 | 15 (8/54) | - | - | 8 (4/50) | - | - | 0 (0/52) | - | - |
| Progression of fibrous proliferation15 | 2 (1/41) | - | 0 (0/37) | - | 0 (0/37) | - | - | - | - |
| Subconjunctival hemorrhage22 | - | 47 (7/15) | - | - | - | 0 (0/7) | - | - | - |
| Syncope17 | 1 (1/90) | - | - | - | - | 0 (0/19) | - | - | - |
| Transient anterior chamber reaction21 | 19 (7/37) | - | 12 (4/33) | - | - | 0 (0/33) | - | - | - |
| Transient intraocular pressure rise17 | 1 (1/90) | - | - | - | - | 0 (0/19) | - | - | - |
| Vitreous hemorrhage15 | 0 (0/41) | - | 3 (1/37) | - | 0 (0/37) | - | - | - | - |
| Worsened renal function17 | 3 (3/90) | - | - | - | - | 0 (0/19) | - | - | - |
The percentages were obtained from all studies reporting at least one event in the bevacizumab group (irrespective of whether combined with other options or alone). Bv = Bevacizumab; Pg = Photocoagulation; Tr = Triamcinolone; PDT = Photodynamic therapy. *Reported causes of death were myocardial infarction and pancreatic cancer.